SSR Miningの空売り状況は、投資家がSSR Miningの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

SSR Mining (NASDAQ:SSRM) 株価情報, 空売り情報

SSR Mining

SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.

SSR Mining Inc

bluebird Board reaffirms unanimous recommendation in support of transaction with Carlyle and SK Capital and recommends all stockholders tender into the current agreement by May 2, 2025
bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. ("Ayrmid") has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (the "Board") reaffirms its recommendation in support of the transaction with Carlyle and SK Capital and recommends all stockholders tender into the current agreement by May 2, 2025.
"Ayrmid's proposal remains highly conditional, despite an extension to the previously agreed-upon timeline to complete confirmatory diligence and submit a binding offer," said Mark Vachon, chairman of the bluebird bio Board of Directors. "bluebird has engaged with Ayrmid on two separate occasions—neither of which has resulted in a binding or fully-financed offer. After careful consideration with our financial and legal advisors, discussions with Hercules Capital, and taking into account that absent a significant infusion of capital, bluebird continues to be at significant risk of defaulting on its loan covenants, the Board unanimously reaffirms its support of the previously announced agreement with Carlyle and SK Capital in the strongest possible terms."

Biotech

News

General

BLUE

bluebird bio Announces That After Three Weeks Of Engagement, Ayrmid Has Not Submitted A Binding Proposal To Acquire Bluebird And Has Not Obtained Necessary Financing

<h3>Gainers</h3>
<ul>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) shares rose 14.5% to $2.65 during Wednesday's pre-market session. The company's market cap stands at $1.6 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock moved upwards by 10.75% to $0.35. The company's market cap stands at $14.4 million. </li>
<li>Diginex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) stock increased by 8.68% to $150.0. The market value of their outstanding shares is at $3.4 billion. </li>
<li>NextTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRP#NASDAQ">NTRP</a>) shares increased by 6.02% to $3.87. The company's market cap stands at $6.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares declined by 30.1% to $2.23 during Wednesday's pre-market session. The market value of their outstanding shares is at $61.1 million. </li>
<li>Kingsoft Cloud Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) stock fell 11.52% to $11.68. The market value of their outstanding shares is at $2.7 billion. </li>
<li>Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) stock declined by 11.05% to $5.72. The market value of their outstanding shares is at $64.2 million. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) stock declined by 10.85% to $0.23. The market value of their outstanding shares is at $1.6 million. </li>
<li>Fatpipe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATN#NASDAQ">FATN</a>) stock decreased by 9.98% to $6.68. The company's market cap stands at $91.6 million. </li>
<li>ARB IOT Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) shares declined by 9.43% to $0.84. The market value of their outstanding shares is at $22.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ARBB

BNAI

CODA

DGNX

FATN

NTRP

Next Technology Holding Inc. - Ordinary Shares

NXTT

SVRE

10 Information Technology Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares rose 12.2% to $1.01 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.3 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) shares increased by 10.67% to $2.8. The market value of their outstanding shares is at $6.6 million. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) shares rose 9.29% to $2.62. The company's market cap stands at $15.6 million. </li>
<li>SAG Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) shares increased by 9.25% to $1.18. The company's market cap stands at $11.6 million. </li>
<li>TH International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THCH#NASDAQ">THCH</a>) shares rose 8.13% to $2.79. The market value of their outstanding shares is at $88.1 million. The company's, Q4 earnings came out yesterday. </li>
<li>LiveWire Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) shares increased by 7.37% to $2.33. The company's market cap stands at $474.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) stock declined by 38.0% to $2.4 during Wednesday's pre-market session. The company's market cap stands at $53.1 million. </li>
<li>Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) shares declined by 16.46% to $4.01. The company's market cap stands at $852.3 million. </li>
<li>Bloomin Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) stock fell 12.69% to $6.61. The company's market cap stands at $561.3 million. </li>
<li>Bassett Furniture Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSET#NASDAQ">BSET</a>) stock fell 9.25% to $15.42. The market value of their outstanding shares is at $135.7 million. </li>
<li>Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) stock decreased by 7.48% to $1.61. The company's market cap stands at $14.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALUR

ATER

BLMN

BSET

CRCT

LCUT

LVWR

RIME

THCH

11 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

Farmers National Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMNB#NASDAQ">FMNB</a>) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.34 by 14.71 percent. This is a 14.71 percent increase over earnings of $0.34 per share from the same period last year.

Earnings

FMNB

Farmers National Banc Q1 Adj $0.39 Beats $0.34 Estimate

2025 GUIDANCE&nbsp; Prologis' guidance for net earnings is included in the table below as well as guidance for Core FFO&#x2A;, which are reconciled in our supplemental information.&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">2025 GUIDANCE&nbsp;&nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Earnings (per diluted share)&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td colspan="1" rowspan="1">Previous</td>
<td colspan="1" rowspan="1">Current</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net earnings attributable to common stockholders</td>
<td colspan="1" rowspan="1">$3.45 to $3.70</td>
<td colspan="1" rowspan="1">$3.45 to $3.70</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Core FFO attributable to common stockholders/unitholders&#x2A;</td>
<td colspan="1" rowspan="1">$5.65 to $5.81</td>
<td colspan="1" rowspan="1">$5.65 to $5.81</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Core FFO attributable to common stockholders/unitholders, excluding Net Promote Income (Expense)&#x2A;</td>
<td colspan="1" rowspan="1">$5.70 to $5.86</td>
<td colspan="1" rowspan="1">$5.70 to $5.86</td>
</tr>
<tr>
<td colspan="3" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="3" rowspan="1">Operations - Prologis Share</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average occupancy</td>
<td colspan="1" rowspan="1">94.50% to 95.50%</td>
<td colspan="1" rowspan="1">94.50% to 95.50%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash Same Store NOI&#x2A;</td>
<td colspan="1" rowspan="1">4.00% to 5.00%</td>
<td colspan="1" rowspan="1">4.00% to 5.00%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Effective Same Store NOI&#x2A;</td>
<td colspan="1" rowspan="1">3.50% to 4.50%</td>
<td colspan="1" rowspan="1">3.50% to 4.50%</td>
</tr>
<tr>
<td colspan="3" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="3" rowspan="1">&nbsp;Strategic Capital (in millions)&nbsp; &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Strategic Capital revenue, excluding promote revenue</td>
<td colspan="1" rowspan="1">$560 to $580</td>
<td colspan="1" rowspan="1">$560 to $580</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Promote Income (Expense)1</td>
<td colspan="1" rowspan="1">$(50)</td>
<td colspan="1" rowspan="1">$(50)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">G&amp;A (in millions)&nbsp;</td>
<td colspan="1" rowspan="1">Previous&nbsp;&nbsp;&nbsp;</td>
<td colspan="1" rowspan="1">Current&nbsp;&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">General &amp; administrative expenses</td>
<td colspan="1" rowspan="1">$440 to $460</td>
<td colspan="1" rowspan="1">$450 to $470</td>
</tr>
<tr>
<td colspan="3" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="3" rowspan="1">Capital Deployment -&nbsp;Prologis Share (in millions)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Development stabilizations</td>
<td colspan="1" rowspan="1">$2,250 to $2,750</td>
<td colspan="1" rowspan="1">$1,900 to $2,300</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Development starts</td>
<td colspan="1" rowspan="1">$2,250 to $2,750</td>
<td colspan="1" rowspan="1">$1,500 to $2,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Acquisitions</td>
<td colspan="1" rowspan="1">$750 to $1,250</td>
<td colspan="1" rowspan="1">$750 to $1,250</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Contributions</td>
<td colspan="1" rowspan="1">$1,500 to $2,000</td>
<td colspan="1" rowspan="1">$150 to $500</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Dispositions</td>
<td colspan="1" rowspan="1">$1,000 to $1,500</td>
<td colspan="1" rowspan="1">$250 to $500</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Realized development gains</td>
<td colspan="1" rowspan="1">$450 to $600</td>
<td colspan="1" rowspan="1">$100 to $250</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Prologis Expects FY25 Core FFO Of $5.65 - $5.81 Vs. $5.73 Consensus

<h3>Gainers</h3>
<ul>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) shares increased by 72.0% to $3.32 during Wednesday's pre-market session. The company's market cap stands at $87.4 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock increased by 17.82% to $3.9. The market value of their outstanding shares is at $59.3 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock rose 12.39% to $0.42. The market value of their outstanding shares is at $66.6 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) shares increased by 10.09% to $10.8. The market value of their outstanding shares is at $81.0 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares moved upwards by 9.06% to $0.98. The company's market cap stands at $16.2 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock rose 8.81% to $1.85. The company's market cap stands at $25.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) stock declined by 61.1% to $0.81 during Wednesday's pre-market session. The company's market cap stands at $25.2 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares declined by 15.13% to $1.74. The company's market cap stands at $7.9 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock decreased by 14.56% to $0.17. The market value of their outstanding shares is at $2.0 million. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) stock fell 13.44% to $6.7. The company's market cap stands at $988.7 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) stock decreased by 11.18% to $0.45. The market value of their outstanding shares is at $38.2 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares declined by 11.03% to $0.96. The market value of their outstanding shares is at $6.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADPT

ASMB

BCDA

FORA

ICAD

IPSC

MIRA

RENB

SXTC

SYRA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) stock rose 20.4% to $4.39 during Wednesday's pre-market session. The company's market cap stands at $1.3 billion. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) stock increased by 20.4% to $1.18. The market value of their outstanding shares is at $20.4 million. </li>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) shares increased by 12.5% to $1.35. The market value of their outstanding shares is at $14.8 million. </li>
<li>HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) shares rose 12.35% to $12.0. The market value of their outstanding shares is at $168.3 million. </li>
<li>Perma-Fix Envirn Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PESI#NASDAQ">PESI</a>) shares moved upwards by 11.57% to $8.0. The market value of their outstanding shares is at $147.4 million. </li>
<li>JFB Construction (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFB#NASDAQ">JFB</a>) stock rose 9.45% to $4.4. The company's market cap stands at $40.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) stock decreased by 24.1% to $6.01 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.1 billion. </li>
<li>SUNation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) shares decreased by 22.93% to $0.03. </li>
<li>Eve Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) shares declined by 20.74% to $3.02. The market value of their outstanding shares is at $898.8 million. </li>
<li>Click Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) shares fell 14.88% to $2.26. The market value of their outstanding shares is at $40.4 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares decreased by 10.65% to $0.23. The company's market cap stands at $46.4 million. The company's, Q4 earnings came out yesterday. </li>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) shares decreased by 10.19% to $2.38. The company's market cap stands at $4.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGLC

CLIK

EVEX

HKPD

HLMN

LNZA

PESI

SUNE

ZBAI

12 Industrials Stocks Moving In Wednesday's Pre-Market Session

AKTX

Akari Therapeutics FY24 Net Loss From Operations $21.6M vs $16.8M YoY

Wolfe Research analyst Timna Tanners upgrades Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) from Peer Perform to Outperform and announces $39 price target.

Upgrades

Price Target

Analyst Ratings

Wolfe Research Upgrades Freeport-McMoRan to Outperform, Announces $39 Price Target

Onfolio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONFO#NASDAQ">ONFO</a>) reported quarterly earnings of $0.01 per share. This is a 102.7 percent increase over losses of $(0.37) per share from the same period last year. The company reported $2.02 million in sales this quarter. This is a 27.56 percent increase over sales of $1.59 million the same period last year.

ONFO

Onfolio Holdings Q4 EPS $0.01 Up From $(0.37) YoY, Sales $2.02M Up From $1.59M YoY

Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) is seeing a significant uptick in on-chain activity and surging burn rates <a href="https://www.benzinga.com/money/shiba-inu-price-prediction">even as prices consolidate.</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001163</td>
<td>$6.9 billion</td>
<td>-2.9%&nbsp;</td>
<td>+6.2%&nbsp;</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1534</td>
<td>$22.8 billion</td>
<td>-4.07%</td>
<td>-5%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.057127</td>
<td>$2.99 billion</td>
<td>-3.2%&nbsp;</td>
<td>-12.4%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Javon Marks remains bullish, stating that SHIB&#8217;s first major breakout target sits over 550% higher at $0.000081.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> (Shiba Inu)&#39;s first breakout target REMAINS OVER 550% AWAY AT $0.000081! <a href="https://t.co/fzqDATl6sn">https://t.co/fzqDATl6sn</a> <a href="https://t.co/iBbYJCK2oV">pic.twitter.com/iBbYJCK2oV</a>
&mdash; JAVON&#x26a1;&#xFE0F;MARKS (@JavonTM1) <a href="https://twitter.com/JavonTM1/status/1912241362121941293?ref_src=twsrc%5Etfw">April 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Crypto Sheriff <a href="https://x.com/Gem_Sheriff/status/1912435154364006707">noted</a> SHIB is at a "good level to take risks," suggesting the recent consolidation at key support could spark a fresh uptrend wave.
Statistics: Shiba Inu&#8217;s burn rate jumped 239.8%, with 70.88 million SHIB removed from circulation in the past day. Notably, 60.5 million SHIB were burned in a single transaction roughly ten hours ago, according to Shibburn data.  
IntoTheBlock data shows large transaction volume increased 5.1% and daily active addresses spiked 39.9% in a single day. Transactions greater than $100,000 increased from 36 to 50. 
Shiba Inu's concentration by large holders remains at 74%, implying long term stability and traders&#8217; confidence in its performance.
Shibariumscan data shows daily transactions having jumped from 3.03 million as of April 14 to 4.28 million as of April 15. 
New Shibarium accounts have increased from 133 to 183.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44778101/shiba-inus-burn-rate-skyrockets-580-as-cryptocurrency-market-rebounds">Shiba Inu&#8217;s Burn Rate Skyrockets 580% as Cryptocurrency Market Rebounds</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Shiba Inu Burns 60 Million SHIB In A Single Transaction: What Is Going On?

Orbic North America, LLC ("Orbic"), an international leader in mobile technology innovation, and GCT Semiconductor Holding, Inc. ("GCT") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>), a leading designer and supplier of advanced 5G and 4G semiconductor solutions, today announced the signing of a letter of intent (LOI) for a partnership to jointly develop and supply an Orbic-branded mobile hotspot and FWA gateway utilizing a Verizon-certified 5G module based on GCT's new 5G chipset. The LOI outlines the framework for collaboration between the parties, including terms related to volume purchases for supply to Verizon and other operators.
As part of the collaborative multi-phase market rollout, Orbic and GCT will initially focus on devices for the Verizon network. Additionally, they will offer versions of the module and devices, including mobile hotspots and CPEs, to other network operators worldwide. GCT will support the joint development and technical efforts by providing core services, including technical expertise, and chipsets for volume production requirements.
"We are thrilled to partner with Orbic, a trusted and established Verizon supplier, to embark on the development and supply of a state-of-the-art 5G module for mobile hotspots and FWA gateways," says John Schlaefer, CEO of GCT. "This collaboration underscores GCT's commitment to innovation and delivering cutting-edge 5G technology solutions. As we work together to create a Verizon-certified 5G module, we are confident that the new Orbic-branded devices using the GCT 5G chipset will set new standards for connectivity and performance."
"By combining Orbic's cutting-edge 5G device innovation with GCT's deep expertise in advanced wireless connectivity, we are strengthening our ability to deliver transformative solutions," said Mike Narula, Founder and CEO of Orbic. "This partnership will not only broaden the reach of our wireless access innovations but also extend the benefits of wireless connectivity without the need for traditional copper connection, all while ensuring exceptional service quality."

Contracts

GCTS

Orbic North America And GCT Semiconductor Signs Letter Of Intent To Develop And Supply Orbic-Branded FWA Gateway And Mobile Hotspot With GCT's Verizon-Certified 5G Module

Events

PDSB

PDS Biotech To Present At American Association of Immunologists' IMMUNOLOGY2025 Annual Meeting May 3-7

New Las Vegas-based facility plans to increase manufacturing and assembly capacity by 400% and accommodate further integration of domestic supply chain
Las Vegas, NV, April 16, 2025 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) ("Richtech Robotics" or "the Company"), a Nevada-based provider of AI-driven service robots, announced the entry of a purchase and sale agreement for the purchase of a piece of land located at 2975 Lincoln Road, Las Vegas, Nevada ("Lincoln Property"), covering approximately 20,000 square feet, to expand its headquarters. The acquisition of the Lincoln Property is scheduled to close on or before May 15, 2025, and is expected to quadruple the Company's assembly and manufacturing footprint for its robotics solutions, supporting increased demand and future growth.
As part of its continued expansion, Richtech Robotics has also signed a lease for a new office in Newark, California, located near the heart of Silicon Valley. Engineers who have undergone training at the Las Vegas headquarters will now begin working out of the Newark location, helping to further develop and deploy the Company's AI and robotics platforms.
 &nbsp;

Richtech Robotics Announces Agreement To Purchase About 20,000 Square Foot Land At Lincoln Property To Expand Its Headquarters; Deal To Close On Or Before May 15, 2025; Terms Not Disclosed

Aptar Commences Clinical Validation Study Of Its SmartTrack In-Vitro-in-Silico Platform For Pressurized Metered-Dose Inhalers

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector.
<h3 class="wp-block-heading">Noble Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>)</h3>
<ul>
<li>Dividend Yield: 10.22%</li>
<li>Citigroup analyst Scott Gruber maintained a Buy rating and cut the price target from $40 to $34 on March 19, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Evercore ISI Group analyst James West downgraded the stock from Outperform to In-Line and cut the price target from $64 to $41 on Jan. 15, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: Noble will report financial results for the first quarter on Monday April 28, after the U.S. market close.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0416">NE news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0416"><img loading="lazy" decoding="async" width="902" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070202/image.png" alt="" class="wp-image-873994" style="width:525px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070202/image.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070202/image-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070202/image-768x713.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Western Midstream Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>)</h3>
<ul>
<li>Dividend Yield: 9.08%</li>
<li>UBS analyst Shneur Gershuni maintained a Neutral rating and cut the price target from $40 to $37 on Nov. 15, 2024. This analyst has an accuracy rate of 80%.</li>
<li>Morgan Stanley analyst Robert Kad downgraded the stock from Equal-Weight to Underweight and slashed the price target from $42 to $40 on Oct. 25, 2024. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On Feb. 26, Western Midstream posted weak quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0416">WES news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0416"><img loading="lazy" decoding="async" width="900" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070236/image-1.png" alt="" class="wp-image-873995" style="width:515px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070236/image-1.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070236/image-1-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070236/image-1-768x713.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
<h3 class="wp-block-heading">Delek US Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DK#NYSE">DK</a>)</h3>
<ul>
<li>Dividend Yield: 8.40%</li>
<li>Raymond James analyst Justin Jenkins maintained an Outperform rating and cut the price target from $24 to $23 on April 9, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Roger Read maintained an Underweight rating and raised the price target from $15 to $16 on March 21, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: Delek US Holdings will release first quarter results before the US stock market opens on Wednesday, May 7.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0416">latest DK news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0416"><img loading="lazy" decoding="async" width="902" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070314/image-1-1.png" alt="" class="wp-image-873996" style="width:560px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070314/image-1-1.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070314/image-1-1-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16070314/image-1-1-768x716.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44811698/jim-cramer-planet-fitness-is-doing-better-than-expected-says-no-to-this-industrial-stock">Jim Cramer: Planet Fitness Is Doing Better Than Expected, Says No To This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

Trading Ideas

Wall Street's Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 5% Dividend Yields

SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated with carbidopa/levodopa
SUNRISE-PD is one of very few clinical trials for a Parkinson's disease treatment to incorporate a decentralized approach option to allow for remote participation
Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson's Foundation
Topline data anticipated in Late 2025 or Early 2026
CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease,&nbsp;today announced that patient enrollment is now open for the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim (NE3107) on motor and non-motor symptoms in patients with Parkinson's disease (PD) who haven't been treated with carbidopa/levodopa. The first patient in the trial has been enrolled, and the Company anticipates topline data to be available in late 2024 or early 2025.
Parkinson's disease is a progressive neurodegenerative disease most often characterized by tremors, muscle rigidity, slowness of movement, postural instability, and difficulties with speech.1 Compelling evidence implicates inflammation and insulin resistance in the initiation and progression of the disease – likely both due to their respective roles in dopamine dysfunction in the brain2-6 and neurodegeneration. Current therapeutic approaches provide only symptomatic relief, but do not modify disease progression.
"Based on promising findings from our earlier Phase 2a trial in patients with moderate to severe symptoms of Parkinson's disease, we've designed the SUNRISE-PD trial to explore bezisterim's impact at an earlier stage with patients needing to go on therapy for the first time to manage their symptoms," said Cuong Do, BioVie's President and CEO. "We believe that together, these two trials have the potential to illustrate the applicability of an anti-inflammatory, insulin-sensitizing drug candidate in treating both early and advanced Parkinson's disease along with providing a foundation for registrational disease-progression studies. Additionally, SUNRISE-PD is to our knowledge one of only a handful of trials to evaluate a potential treatment for Parkinson's disease while allowing patients to participate remotely through a decentralized trial site, broadening access for this focused study population."

BIVI

Biovie Opens Patient Enrollment For Phase 2 Sunrise-Pd Clinical Trial Evaluating The Safety And Efficacy Of Bezisterim On Motor And Non-Motor Symptoms In Patients With Parkinson's Disease Who Haven't Been Treated With Carbidopa/Levodopa. Topline Data Expected In Late 2025 Or Early 2026

HC Wainwright &amp; Co. analyst Ed Arce reiterates MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) with a Buy and maintains $12 price target.

Reiteration

MTVA

HC Wainwright & Co. Reiterates Buy on MetaVia, Maintains $12 Price Target

Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) reported quarterly earnings of $1.42 per share which beat the analyst consensus estimate of $1.38 by 2.9 percent. This is a 10.94 percent increase over earnings of $1.28 per share from the same period last year. The company reported quarterly sales of $2.00 billion which missed the analyst consensus estimate of $2.04 billion by 1.80 percent. This is a 9.35 percent increase over sales of $1.83 billion the same period last year.

Earnings Beats

Earnings Misses

Prologis Q1 2025 FFO $1.42 Beats $1.38 Estimate, Sales $2.00B Miss $2.04B Estimate

In the preceding three months, 8 analysts have released ratings for Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $15.12, a high estimate of $18.00, and a low estimate of $10.00. Highlighting a 10.43% decrease, the current average has fallen from the previous average price target of $16.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1744804920_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Grocery Outlet Holding is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Corey Tarlowe &#x7C;Jefferies &#x7C;Raises &#x7C;Buy &#x7C; $18.00&#x7C;$13.00 &#x7C; 
&#x7C;Kate McShane &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Sell &#x7C; $11.00&#x7C;$14.00 &#x7C; 
&#x7C;Anthony Chukumba &#x7C;Loop Capital &#x7C;Lowers &#x7C;Hold &#x7C; $13.00&#x7C;$16.00 &#x7C; 
&#x7C;Simeon Gutman &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underperform &#x7C; $10.00&#x7C;$13.00 &#x7C; 
&#x7C;Anthony Bonadio &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $18.00&#x7C;$23.00 &#x7C; 
&#x7C;Robert Ohmes &#x7C;B of A Securities &#x7C;Lowers &#x7C;Neutral &#x7C; $17.00&#x7C;$20.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Market Perform &#x7C; $16.00&#x7C;$18.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $18.00&#x7C;$18.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Grocery Outlet Holding. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Grocery Outlet Holding compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Grocery Outlet Holding's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Grocery Outlet Holding's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Grocery Outlet Holding analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Grocery Outlet Holding</h2>
Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
<h3>Financial Milestones: Grocery Outlet Holding's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Grocery Outlet Holding's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 10.91%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Grocery Outlet Holding's net margin excels beyond industry benchmarks, reaching 0.21%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Grocery Outlet Holding's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Grocery Outlet Holding's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.07%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.38.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Grocery Outlet Holding Through 8 Analysts

Press Releases

SSR Mining Announces the Acquisition of the Cripple Creek & Victor Gold Mine From Newmont

SSR Mining Celebrates 5 Million Ounces of Gold Production From Marigold

SSR Mining Announces Expert Findings on Cause of the Çöpler Incident

SSR Mining to Announce Fourth Quarter and Full-Year 2024 Consolidated Financial Results on February 18, 2025

SSR Mining Appoints Laura Mullen to Board of Directors

SSR Mining Reports Fourth Quarter and Full-Year 2024 Results

SSR Mining to Voluntarily Delist From ASX

SSR Mining Announces Closing of Cripple Creek & Victor Acquisition

SSR Mining Provides 2025 Operating Guidance

SSR Mining to Announce First Quarter 2025 Consolidated Financial Results on May 6, 2025

Comments

SSR Mining

空売り

SSR Mining (NASDAQ:SSRM) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル